• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

VINCI CAPITAL

edit

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.

Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operational background in growth, turn-around, consolidation, IPOs and M&A situations.

Milestones

edit

• 
  VINCI CAPITAL invested in Anergis. (3/28/11)
  Posted 3/28/11 at 7:59pm via fiercebiotech.com
• 
  VINCI CAPITAL invested in Kuros Biosurgery. (10/1/05)
  Posted 8/31/10 at 12:41am via kuros.ch
• 
  VINCI CAPITAL invested in Kuros Biosurgery. (1/1/05)
  Posted 8/30/10 at 2:46am via kuros.ch
• 
  VINCI CAPITAL invested in SolvAxis. (2/2/10)
  Posted 7/21/10 at 2:24am
• 
  VINCI CAPITAL invested in immatics biotechnologies. (4/15/05)
  Posted 7/5/10 at 3:14am
• 
  VINCI CAPITAL invested in Datamars. (11/10/06)
  Posted 5/27/10 at 1:50am
• 
  VINCI CAPITAL invested in Evolva. (12/11/09)
  Posted 12/16/09 at 1:16am via dowjones.com
• 
  VINCI CAPITAL invested in Evolva. (12/7/09)
  Posted 10/28/09 at 7:50am via onbiovc.com
• 
  VINCI CAPITAL invested in Omnisens. (9/10/08)
  Posted 7/22/09 at 7:41pm via omnisens.ch

Investments

Videos

Sources

1. Startup biotech lands $20M A round for Ph2 allergy trial (fiercebiotech.com) [edit]
2. Cap Funding Report [edit]
3. Evolva Goes Public In Reverse Merger, Raises $43M (fis.dowjones.com) [edit]
4. Evolva, SA: Series B $27.5M (onbiovc.com) [edit]
5. OMNISENS RAISES CHF 6,000,000 VENTURE FUNDING (omnisens.ch) [edit]
6. Cap Funding Report [edit]
7. KUROS BIOSURGERY AG RAISES CHF 5.6M (€ 3.6M) IN ADDITIONAL FUNDING (kuros.ch) [edit]
8. Cap Funding Report [edit]
9. KUROS BIOSURGERY AG EXERCISES OPTION FOR CHF 6.1M (€ 4M) INVESTMENT (kuros.ch) [edit]